• Je něco špatně v tomto záznamu ?

Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: A retrospective registry-based study

M. Koziar Vašáková, J. Gregor, N. Mogulkoc, MR. Kramer, K. Lewandowska, M. Šterclová, V. Müller, R. Slivka, M. Studnicka, M. Plačková, M. Žurková, J. Tekavec-Trkanjec, M. Doubková, P. Ovesná, EMPIRE investigators

. 2024 ; 234 (-) : 107791. [pub] 20240908

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, pozorovací studie, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003664

BACKGROUND: There is a lack of data on the long-term effect of nintedanib on survival in specific groups of idiopathic pulmonary fibrosis (IPF) patients with different phenotypes. We investigated the outcomes of nintedanib therapy in an observational study of a large multicentre real-world cohort of IPF patients with various initial characteristics. METHODS: The analysis included IPF patients treated with nintedanib (NIN) and IPF patients not receiving antifibrotic treatment (NAF) enrolled for the EMPIRE registry in 2015-2020. The patients were stratified according to their initial FVC predicted, dyspnoea, UIP pattern and age. All-cause mortality and annual rate of FVC decline were the main endpoints. Cox proportional hazards model for survival assessment and linear mixed-effects model for FVC decline modelling were used. RESULTS: A total of 869 NIN patients and 691 NAF patients were eligible for the analysis. The annual FVC decline rate was significantly different (adjusted values -0.053 l/yr vs -0.122 l/yr; p = 0.001). The adjusted hazard ratio (HR) for mortality was 0.40 (95 % CI 0.3 to 0.53, p < 0.001). The most significant effect of nintedanib was demonstrated in patients with impaired lung function, i.e., with an FVC predicted to be less than 80 % and a NYHA II to IV. Nintedanib therapy also reduced the difference in survival between men and women. CONCLUSIONS: Modelling confirmed that NIN therapy reduced differences in OS between patients with better and worse initial conditions and prognosis. Our results indicate that NIN is particularly beneficial for patients with advanced IPF and more severe phenotypes. TRIAL REGISTRATION: EMPIRE was registered as a non-interventional post-registration study at the State Institute for Drug Control of the Czech Republic under ID 1412080000 on December 8, 2014.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003664
003      
CZ-PrNML
005      
20250206104608.0
007      
ta
008      
250121e20240908enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.rmed.2024.107791 $2 doi
035    __
$a (PubMed)39255912
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Koziar Vašáková, Martina $u Department of Respiratory Medicine, Thomayer University Hospital, Prague, Czech Republic. Electronic address: martina.koziarvasakova@ftn.cz
245    10
$a Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: A retrospective registry-based study / $c M. Koziar Vašáková, J. Gregor, N. Mogulkoc, MR. Kramer, K. Lewandowska, M. Šterclová, V. Müller, R. Slivka, M. Studnicka, M. Plačková, M. Žurková, J. Tekavec-Trkanjec, M. Doubková, P. Ovesná, EMPIRE investigators
520    9_
$a BACKGROUND: There is a lack of data on the long-term effect of nintedanib on survival in specific groups of idiopathic pulmonary fibrosis (IPF) patients with different phenotypes. We investigated the outcomes of nintedanib therapy in an observational study of a large multicentre real-world cohort of IPF patients with various initial characteristics. METHODS: The analysis included IPF patients treated with nintedanib (NIN) and IPF patients not receiving antifibrotic treatment (NAF) enrolled for the EMPIRE registry in 2015-2020. The patients were stratified according to their initial FVC predicted, dyspnoea, UIP pattern and age. All-cause mortality and annual rate of FVC decline were the main endpoints. Cox proportional hazards model for survival assessment and linear mixed-effects model for FVC decline modelling were used. RESULTS: A total of 869 NIN patients and 691 NAF patients were eligible for the analysis. The annual FVC decline rate was significantly different (adjusted values -0.053 l/yr vs -0.122 l/yr; p = 0.001). The adjusted hazard ratio (HR) for mortality was 0.40 (95 % CI 0.3 to 0.53, p < 0.001). The most significant effect of nintedanib was demonstrated in patients with impaired lung function, i.e., with an FVC predicted to be less than 80 % and a NYHA II to IV. Nintedanib therapy also reduced the difference in survival between men and women. CONCLUSIONS: Modelling confirmed that NIN therapy reduced differences in OS between patients with better and worse initial conditions and prognosis. Our results indicate that NIN is particularly beneficial for patients with advanced IPF and more severe phenotypes. TRIAL REGISTRATION: EMPIRE was registered as a non-interventional post-registration study at the State Institute for Drug Control of the Czech Republic under ID 1412080000 on December 8, 2014.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a antifibrotické látky $x terapeutické užití $7 D000088962
650    12
$a idiopatická plicní fibróza $x farmakoterapie $x mortalita $x patofyziologie $7 D054990
650    12
$a indoly $x terapeutické užití $7 D007211
650    _2
$a fenotyp $7 D010641
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a registrace $7 D012042
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
650    _2
$a vitální kapacita $7 D014797
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Gregor, Jakub $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Mogulkoc, Nesrin $u Department of Chest Diseases, Faculty of Medicine, Ege University, Izmir, Turkey
700    1_
$a Kramer, Mordechai R $u Rabin Medical Centre, Petah Tikva, Israel
700    1_
$a Lewandowska, Katarzyna $u First Department of Pulmonary Diseases, Institute of Tuberculosis and Lung Diseases, Warsaw, Poland
700    1_
$a Šterclová, Martina $u Department of Respiratory Medicine, Thomayer University Hospital, Prague, Czech Republic
700    1_
$a Müller, Veronika $u Department of Pulmonology, Faculty of Medicine, Semmelweis University, Budapest, Hungary
700    1_
$a Slivka, Róbert $u National Institute of Tuberculosis, Respiratory Diseases and Chest Surgery, Vyšné Hagy, Slovakia
700    1_
$a Studnicka, Michael $u Department of Respiratory Medicine, Paracelsus Medical University, Salzburg, Austria
700    1_
$a Plačková, Martina $u Department of Pneumology, University Hospital, Ostrava, Czech Republic
700    1_
$a Žurková, Monika $u Department of Respiratory Medicine, University Hospital, Olomouc, Czech Republic
700    1_
$a Tekavec-Trkanjec, Jasna $u Department of Pulmonology, University Hospital Dubrava, Zagreb, Croatia
700    1_
$a Doubková, Martina $u Department of Pulmonary Diseases and Tuberculosis, Faculty of Medicine, Masaryk University and University Hospital, Brno, Czech Republic
700    1_
$a Ovesná, Petra $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
710    2_
$a EMPIRE investigators
773    0_
$w MED00004105 $t Respiratory medicine $x 1532-3064 $g Roč. 234 (20240908), s. 107791
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39255912 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104604 $b ABA008
999    __
$a ok $b bmc $g 2263427 $s 1239671
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 234 $c - $d 107791 $e 20240908 $i 1532-3064 $m Respiratory medicine $n Respir Med $x MED00004105
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace